Art. -Nr.: HY-14879

Avibactam free acid

(Synonyms: NXL-104 free acid)

94 Cited Publications

Kundenbewertung

Based on 94 publication(s) in Google Scholar

Avibactam (NXL-104) free acid is a covalent and reversible non-β-lactam β-lactamase inhibitor which inhibits β-lactamase TEM-1 and CTX-M-15 with IC₅₀s of 8 nM and 5 nM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.27%
CAS. Nr.: 1192500-31-4
Formel: C₇H₁₁N₃O₆S
Molecular Weight:265.24

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Avibactam free acid Chemical Structure

CAS. Nr.: 1192500-31-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (94)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC₅₀: 5 nM (CTX-M-15), 8 nM (TEM-1)^[1]

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

In Vitro

Avibactam is a molecule with little antibacterial activity, that inhibits class A and C β-lactamases, but not metallo types and Acinetobacter OXA carbapenemases^[2].
Ceftazidime (HY-B0593)-Avibactam (0-256 mg/L) inhibits 16 bla_KPC-2 positive and 1 of bla_OXA-232 positive Klebsiella pneumonia growth with MIC₅₀ and MIC₉₀ for both 8 mg/L^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ceftazidime-Avibactam (0.375 mg/g; s.c.; q8h for 10 days) has a significant effect on the bacteria and led to a certain therapeutic efficacy in K. pneumoniae strain Y8 infected mouse model^[3].
Avibactam (64 mg/kg; s.c.; once) shows mean estimated half-life in plasma in the terminal phase of 0.24 h in Pseudomonas aeruginosa infected neutropenic mice with lung infection^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Six-week-old BALB/c mice (female), K. pneumoniae strain Y8 infection model^[4]
Dosage:

0.375 mg/g in combination with Ceftazidime
Administration:

Subcutaneous injection, 4 h post infection and given every 8 h for 10 days
Result:

70% of infection group mice died within 4 days, and all mice in the PBS group died within 13 days. All treatment group mice survived at 10 days post infection with the antibiotic applied every 8 h, whereas 100% of mice in this group died within 4 days after the antibiotic treatment stopped. The spleen and liver of treatment group mice showed lower CFU counts, as compare with that of infected group.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1192500-31-4
Appearance Solid
Molecular Weight 265.24
Formel C₇H₁₁N₃O₆S
Color White to off-white
SMILES

O=S(ON1[C@]2([H])CC[C@@H](C(N)=O)[N@@](C2)C1=O)(O)=O
Synonyms

NXL-104 free acid
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (94)

All Bio/Physico-chemical AssayRT-PCRIn Vivo Efficacy StudyWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nature

Blood culture-free ultra-rapid antimicrobial susceptibility testing. [Abstract]

2024 Aug;632(8026):893-902. PMID: 39048820
Biosens Bioelectron

Rapid personalized AMR diagnostics using two-dimensional antibiotic resistance profiling strategy employing a thermometric NDM-1 biosensor. [Abstract]

2021 Dec 1:193:113526. PMID: 34325239

Avibactam free acid purchased from MedChemExpress. Usage Cited in: Biosens Bioelectron. 2021 Dec 1:193:113526. [Abstract]

Avibactam sodium (AVI: 6.3-50 mg/L) in the presence or absence of 200 mg/L ceftriaxone and/or 0.8 U/L CTX-M-14.

Avibactam free acid purchased from MedChemExpress. Usage Cited in: Biosens Bioelectron. 2021 Dec 1:193:113526. [Abstract]

Analysis of mixed mock samples containing 0.8 U/L each of NDM-1/CTX-M-14 were incubated with penicillin, ceftriaxone, cefepime, cefoxitin or meropenem (200 mg/L) in the presence and absence of 25 mg/L Avibactam sodium (AVI) for 15 min, then the NDM-1/CTX-M-14 treated and untreated antibiotic samples were analyzed.
Cell Rep

ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. [Abstract]

2024 Nov 9;43(11):114962. PMID: 39522165

Avibactam free acid purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 9;43(11):114962. [Abstract]

SREBP2 target gene transcript levels after treatment with Avibactam (0.69 μM, 24 h) analyzed by qPCR. Actin Beta (ACTB) was used as a reference gene.

Avibactam free acid purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 9;43(11):114962. [Abstract]

S-acylation levels of SCAP in Huh7 cells treated with Avibactam (0.69 μM, 24 h).

Avibactam free acid purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 9;43(11):114962. [Abstract]

Protein levels of SCAP and its downstream target proteins in Huh7 cells following treatment with Avibactam (0.69 μM, 24 h).
RSC Adv

Metallo-β-lactamases immobilized by magnetic zeolitic imidazolate frameworks-8 for degradation of β-lactam antibiotics in an aqueous environment. [Abstract]

2023 Nov 30;13(49):34884-34890. PMID: 38035241
J Clin Microbiol

Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test. [Abstract]

2023 May 23;61(5):e0164722. PMID: 37070979
J Clin Microbiol

NitroSpeed-Carba NP Test for Rapid Detection and Differentiation between Different Classes of Carbapenemases in Enterobacterales. [Abstract]

2020 Aug 24;58(9):e00932-20. PMID: 32580949
Int J Mol Sci

Molecular Basis of AmpC β-Lactamase Induction by Avibactam in Pseudomonas aeruginosa: PBP Occupancy, Live Cell Binding Dynamics and Impact on Resistant Clinical Isolates Harboring PDC-X Variants. [Abstract]

2021 Mar 17;22(6):3051. PMID: 33802668
Antibiotics (Basel)

2024 May 1, 13(5), 416.
Antibiotics (Basel)

Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in Acinetobacter baumannii. [Abstract]

2023 Jul 20;12(7):1212. PMID: 37508308
Antibiotics (Basel)

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae. [Abstract]

2022 Sep 20;11(10):1280. PMID: 36289937
Antibiotics (Basel)

Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]

2021 Nov 3;10(11):1341. PMID: 34827279
Antibiotics (Basel)

Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]

2021 Sep 14;10(9):1110. PMID: 34572692
BMC Microbiol

Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China. [Abstract]

2020 Jun 29;20(1):187. PMID: 32600252
BMC Microbiol

Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam. [Abstract]

2019 Nov 1;19(1):240. PMID: 31675928
Molecules

Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]

2025 Mar 9;30(6):1224. PMID: 40142001
Int J Antimicrob Agents

Resistance to aztreonam-avibactam among clinical isolates of E. coli is primarily mediated by altered penicillin binding protein 3 and impermeability. [Abstract]

2024 Sep;64(3):107256. PMID: 38925228
Int J Antimicrob Agents

MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. [Abstract]

2024 Aug;64(2):107206. PMID: 38754526
Int J Antimicrob Agents

Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]

2018 Aug;52(2):269-271. PMID: 29559273
PLoS Pathog

Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. [Abstract]

2024 Dec 31;20(12):e1012783. PMID: 39739989
Sci Rep

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. [Abstract]

2022 Oct 7;12(1):16814. PMID: 36207358
Int J Infect Dis

Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan. [Abstract]

2026 Feb:163:108279. PMID: 41349864
Int J Infect Dis

Evaluation of NitroSpeed-Carba NP test for rapid identification among different classes of carbapenemases in Enterobacterales and Pseudomonas aeruginosa. [Abstract]

2021 May:106:415-420. PMID: 33864920
Int J Infect Dis

Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam. [Abstract]

2020 Apr:93:252-257. PMID: 32061861
ACS Infect Dis

Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease. [Abstract]

2025 Apr 1. PMID: 40168319
iScience

The oxacillinase variant, OXA-1152, in Pandoraea sputorum contributes to discrepancies in carbapenem resistance. [Abstract]

2025 Mar 28;28(5):112311. PMID: 40454099
ACS Infect Dis

Atypically Modified Carbapenem Antibiotics Display Improved Antimycobacterial Activity in the Absence of β-Lactamase Inhibitors. [Abstract]

2021 Aug 13;7(8):2425-2436. PMID: 34191496
Antimicrob Agents Chemother

Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. [Abstract]

2026 Jun 3;70(6):e0126725. PMID: 42053451
Antimicrob Agents Chemother

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. [Abstract]

2026 Mar 23:e0186025. PMID: 41870042
Antimicrob Agents Chemother

A genomics-informed mechanism-based pharmacokinetic/pharmacodynamic model of cefiderocol and ceftazidime/avibactam against carbapenem-resistant Achromobacter xylosoxidans. [Abstract]

2026 Mar 4;70(3):e0126325. PMID: 41586494
Antimicrob Agents Chemother

PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate. [Abstract]

2025 May 7;69(5):e0179724. PMID: 40227072
Antimicrob Agents Chemother

Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination. [Abstract]

2025 Mar 5;69(3):e0173624. PMID: 39918316
Antimicrob Agents Chemother

Prediction of higher ceftazidime-avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis. [Abstract]

2025 Mar 5;69(3):e0151824. PMID: 39912660
Antimicrob Agents Chemother

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]

2024 Nov 6;68(11):e0077524. PMID: 39365068
Antimicrob Agents Chemother

An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from in vitro time-kill experiments against multidrug-resistant Klebsiella pneumoniae isolates. [Abstract]

2023 Oct 18;67(10):e0030123. PMID: 37681977
Antimicrob Agents Chemother

The in vitro effect of new combinations of carbapenem-β-lactamase inhibitors for Mycobacterium abscessus. [Abstract]

2023 Oct 18;67(10):e0052823. PMID: 37671880
Antimicrob Agents Chemother

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]

2023 Jul 18;67(7):e0033923. PMID: 37255469
Antimicrob Agents Chemother

Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. [Abstract]

2023 Jun 15;67(6):e0160322. PMID: 37199612
Antimicrob Agents Chemother

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. [Abstract]

2023 Feb 16;67(2):e0145922. PMID: 36688684
Antimicrob Agents Chemother

A Two Amino Acid Duplication, L167E168, in the Ω-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A β-Lactamase. [Abstract]

2022 Jun 21;66(6):e0240221. PMID: 35647648
Antimicrob Agents Chemother

Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae. [Abstract]

2020 Sep 21;64(10):e00409-20. PMID: 32660988
Antimicrob Agents Chemother

β-Lactamase of Mycobacterium tuberculosis Shows Dynamics in the Active Site That Increase upon Inhibitor Binding. [Abstract]

2020 Feb 21;64(3):e02025-19. PMID: 31871087
Antimicrob Agents Chemother

CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems. [Abstract]

2019 Sep 9;63(12):e01515-19. PMID: 31527021
Antimicrob Agents Chemother

Synergistic Combinations and Repurposed Antibiotics Active against the Pandrug-Resistant Klebsiella pneumoniae Nevada Strain. [Abstract]

2019 Aug 23;63(9):e01374-19. PMID: 31307981
Antimicrob Agents Chemother

Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa. [Abstract]

2018 Dec 21;63(1):e01809-18. PMID: 30323045
Antimicrob Agents Chemother

Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae. [Abstract]

2018 Sep 24;62(10):e00873-18. PMID: 30061285
Antimicrob Agents Chemother

Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. [Abstract]

2018 Jul 27;62(8):e00414-18. PMID: 29760136
Antimicrob Agents Chemother

The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination. [Abstract]

2018 Jul 27;62(8):e00433-18. PMID: 29784837
Antimicrob Agents Chemother

First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae. [Abstract]

2018 May 25;62(6):e00282-18. PMID: 29712652
Antimicrob Agents Chemother

Cyclic Boronates Inhibit All Classes of β-Lactamases. [Abstract]

2017 Mar 24;61(4):e02260-16. PMID: 28115348
J Antimicrob Chemother

Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]

2026 Feb 2;81(3):dkag034. PMID: 41648989
J Antimicrob Chemother

Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies. [Abstract]

2026 Jan 19;81(2):dkaf495. PMID: 41549665
J Antimicrob Chemother

Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]

2025 Nov 5:dkaf408. PMID: 41206063
J Antimicrob Chemother

Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model. [Abstract]

2025 Oct 27:dkaf388. PMID: 41140026
Microbiol Spectr

Emergence of drug-resistant Klebsiella pneumoniae phylogroups (K. quasipneumoniae and K. variicola) causing human infections. [Abstract]

2025 Sep 2;13(9):e0019825. PMID: 40778769
J Antimicrob Chemother

Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes. [Abstract]

2025 Sep 29:dkaf360. PMID: 41016856
Microbiol Spectr

Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against Enterobacterales isolates. [Abstract]

2024 Oct 3;12(10):e0095324. PMID: 39225487
J Antimicrob Chemother

Performance of disk diffusion method for aztreonam in combination with avibactam against Enterobacteriales. [Abstract]

2024 Jun 3;79(6):1309-1312. PMID: 38564262
Microbiol Spectr

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients. [Abstract]

2023 Dec 12;11(6):e0304723. PMID: 37982634
Microbiol Spectr

Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. [Abstract]

2023 Jun 15;11(3):e0069223. PMID: 37093051
J Antimicrob Chemother

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. [Abstract]

2023 Apr 3;78(4):983-990. PMID: 36775993
Microbiol Spectr

PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. [Abstract]

2023 Feb 14;11(1):e0303822. PMID: 36475840
Microbiol Spectr

Plasmid-Borne AFM Alleles in Pseudomonas aeruginosa Clinical Isolates from China. [Abstract]

2022 Oct 26;10(5):e0203522. PMID: 36000902
Microbiol Spectr

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies. [Abstract]

2022 Oct 26;10(5):e0139022. PMID: 35972286
J Antimicrob Chemother

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa. [Abstract]

2022 Sep 30;77(10):2803-2808. PMID: 35848936

Avibactam free acid purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2022 Sep 30;77(10):2803-2808. [Abstract]

In vivo change in log10 cfu/thigh of each isolate treated with saline control, Ceftazidime 2 g IV q8h 2 h infusion HSR, Ceftazidime/Avibactam 2.5 g q8h 2 h infusion HSR or meropenem 2 g q8h 3 h infusion HSR for three P. aeruginosa with inserted GES β-lactamases. (a) PSA 2136, with inserted GES-1 (ESBL). (b) PSA 2137, with inserted GES-5 (carbapenemase). (c) PSA 2138, with inserted GES-15. P values in the boxes represent the results from one-way ANOVA; P values are presented if between-group differences were present. The x-axis describes the treatment HSR [MIC (mg/L), % fT>MIC]. CAZ, Ceftazidime; CAZ-AVI, Ceftazidime/Avibactam; MEM, meropenem.
J Antimicrob Chemother

In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]

2021 Jul 15;76(8):2071-2078. PMID: 33956969
J Antimicrob Chemother

Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]

2021 Feb 11;76(3):653-658. PMID: 33258923
J Antimicrob Chemother

Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. [Abstract]

2020 Sep 1;75(9):2609-2615. PMID: 32591806
J Infect Dis

Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance. [Abstract]

2019 Jul 2;220(3):484-493. PMID: 30923801
J Antimicrob Chemother

Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. [Abstract]

2017 Sep 1;72(9):2483-2488. PMID: 28637339
J Antimicrob Chemother

High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. [Abstract]

2017 Jul 1;72(7):1930-1936. PMID: 28333323

Avibactam free acid purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2017 Jul 1;72(7):1930-1936. [Abstract]

Total β-lactamase activity for bacterial lysates is measured using the chromogenic substrate nitrocefin, with or without Avibactam at 4 mg/L. (b) GR20263 hydrolysis activity of different bacterial lysates is determined with or without Avibactam at 4 mg/L.
Open Forum Infect Dis

2026 Mar 26.
Open Forum Infect Dis

Successful Treatment of Recurrent Extensively Drug-Resistant Elizabethkingia anophelis Bacteremia Secondary to Ventricular Assist Device-Associated Infection. [Abstract]

2024 Oct 11;11(11):ofae611. PMID: 39494452
Infect Drug Resist

2026 May 8;19.
Eur J Clin Microbiol Infect Dis

Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]

2025 Sep 29. PMID: 41023358
Eur J Clin Microbiol Infect Dis

In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. [Abstract]

2025 Mar;44(3):571-585. PMID: 39704920
Eur J Clin Microbiol Infect Dis

In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [Abstract]

2025 Feb;44(2):277-284. PMID: 39589655
Adv Ther (Weinh)

2024 Jan 12.
Infect Drug Resist

In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China. [Abstract]

2021 Jun 30;14:2499-2507. PMID: 34234477
Infect Drug Resist

Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem. [Abstract]

2020 Aug 18:13:2883-2890. PMID: 32903882
Biomed Res Int

In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]

2018 Jul 2:2018:3579832. PMID: 30065936
Infect Genet Evol

Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]

2025 Sep:133:105780. PMID: 40480594
Int J Med Microbiol

In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales. [Abstract]

2021 Oct;70(10). PMID: 34605763
J Med Microbiol

In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. [Abstract]

2020 Jul;69(7):928-931. PMID: 32584214
Microb Drug Resist

SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible Klebsiella pneumoniae. [Abstract]

2020 Apr;26(4):334-340. PMID: 31651221
Acta Microbiol Immunol Hung

Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey. [Abstract]

2021 Jul 29;68(4):256-261. PMID: 34324428
J Infect Dev Ctries

An unequivocal superbug: PDR Klebsiella pneumoniae with an arsenal of resistance and virulence factor genes. [Abstract]

2021 Mar 31;15(3):404-414. PMID: 33839716
Res Sq

2026 Mar 9.
Res Sq

2026 Mar 10.
bioRxiv

2026 Jan 23.
University of Skovde

2025.
Seoul National University

2025 Feb.
bioRxiv

Rapid Emergence of Resistance to Broad-Spectrum Direct Antimicrobial Activity of Avibactam. [Abstract]

2024 Sep 25:2024.09.25.615047. PMID: 39386481
Preprints

2023 Jun 21.
bioRxiv

2021 Mar 13.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (471.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7702 mL

18.8509 mL

37.7017 mL

5 mM

0.7540 mL

3.7702 mL

7.5403 mL

10 mM

0.3770 mL

1.8851 mL

3.7702 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ehmann DE, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. [Content Brief]

[2]. Livermore DM, et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother. 2012 Jun;67(6):1354-8. [Content Brief]

[3]. Berkhout J, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304. [Content Brief]

[4]. Zhang W, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018 Nov 21;7:142. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7702 mL	18.8509 mL	37.7017 mL	94.2543 mL
	5 mM	0.7540 mL	3.7702 mL	7.5403 mL	18.8509 mL
	10 mM	0.3770 mL	1.8851 mL	3.7702 mL	9.4254 mL
	15 mM	0.2513 mL	1.2567 mL	2.5134 mL	6.2836 mL
	20 mM	0.1885 mL	0.9425 mL	1.8851 mL	4.7127 mL
	25 mM	0.1508 mL	0.7540 mL	1.5081 mL	3.7702 mL
	30 mM	0.1257 mL	0.6284 mL	1.2567 mL	3.1418 mL
	40 mM	0.0943 mL	0.4713 mL	0.9425 mL	2.3564 mL
	50 mM	0.0754 mL	0.3770 mL	0.7540 mL	1.8851 mL
	60 mM	0.0628 mL	0.3142 mL	0.6284 mL	1.5709 mL
	80 mM	0.0471 mL	0.2356 mL	0.4713 mL	1.1782 mL
	100 mM	0.0377 mL	0.1885 mL	0.3770 mL	0.9425 mL

Keywords

Avibactam free acid

94 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Avibactam free acid

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

EMA-Approved Drug Library

Heterocyclic Compound Library

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Avibactam free acid

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (94)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Avibactam free acid

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

EMA-Approved Drug Library

Heterocyclic Compound Library

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Avibactam free acid

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (94)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Avibactam free acid Related Classifications

HY-14879 Related Classifications